FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096008082> ?p ?o ?g. }

• W2096008082 abstract "Up to 30% of patients with food allergies have clinical reactivity to more than one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under investigation. Pilot data have shown that omalizumab may hasten the ability to tolerate over 4 g of food allergen protein. To evaluate the safety and dose tolerability of a Phase 1 Single Site OIT protocol using omalizumab to allow for a faster and safe desensitization to multiple foods simultaneously. Participants with multiple food allergies received OIT for up to 5 allergens simultaneously with omalizumab (rush mOIT). Omalizumab was administered for 8 weeks prior to and 8 weeks following the initiation of a rush mOIT schedule. Home reactions were recorded with diaries. Twenty-five (25) participants were enrolled in the protocol (median age 7 years). For each included food, participants had failed an initial double-blind placebo-controlled food challenge at a protein dose of 100 mg or less. After pre-treatment with omalizumab, 19 participants tolerated all 6 steps of the initial escalation day (up to 1250 mg of combined food proteins), requiring minimal or no rescue therapy. The remaining 6 were started on their highest tolerated dose as their initial daily home doses. Participants reported 401 reactions per 7,530 home doses (5.3%) with a median of 3.2 reactions per 100 doses. Ninety-four percent (94%) of reactions were mild. There was one severe reaction. Participants reached their maintenance dose of 4,000 mg protein per allergen at a median of 18 weeks. These phase 1 data demonstrate that rush OIT to multiple foods with 16 weeks of treatment with omalizumab could allow for a fast desensitization in subjects with multiple food allergies. Phase 2 randomized controlled trials are needed to better define safety and efficacy parameters of multi OIT experimental treatments with and without omalizumab." @default.
• W2096008082 created "2016-06-24" @default.
• W2096008082 creator A5005253283 @default.
• W2096008082 creator A5018170532 @default.
• W2096008082 creator A5022662950 @default.
• W2096008082 creator A5028760615 @default.
• W2096008082 creator A5033295100 @default.
• W2096008082 creator A5038468938 @default.
• W2096008082 creator A5050275340 @default.
• W2096008082 creator A5052394575 @default.
• W2096008082 creator A5054811067 @default.
• W2096008082 creator A5055694689 @default.
• W2096008082 creator A5058037343 @default.
• W2096008082 creator A5062378663 @default.
• W2096008082 creator A5077549687 @default.
• W2096008082 creator A5080962883 @default.
• W2096008082 date "2014-02-27" @default.
• W2096008082 modified "2023-10-01" @default.
• W2096008082 title "Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab" @default.
• W2096008082 cites W1594531404 @default.
• W2096008082 cites W1963754158 @default.
• W2096008082 cites W1971723752 @default.
• W2096008082 cites W1973173221 @default.
• W2096008082 cites W1975780852 @default.
• W2096008082 cites W1976771675 @default.
• W2096008082 cites W1978348694 @default.
• W2096008082 cites W1988733403 @default.
• W2096008082 cites W1991943330 @default.
• W2096008082 cites W1994095603 @default.
• W2096008082 cites W2001547196 @default.
• W2096008082 cites W2009542266 @default.
• W2096008082 cites W2012513978 @default.
• W2096008082 cites W2014953142 @default.
• W2096008082 cites W2020584035 @default.
• W2096008082 cites W2022764839 @default.
• W2096008082 cites W2024547469 @default.
• W2096008082 cites W2028156173 @default.
• W2096008082 cites W2031202979 @default.
• W2096008082 cites W2033222579 @default.
• W2096008082 cites W2033385733 @default.
• W2096008082 cites W2041163847 @default.
• W2096008082 cites W2041899741 @default.
• W2096008082 cites W2043554125 @default.
• W2096008082 cites W2050928602 @default.
• W2096008082 cites W2065357866 @default.
• W2096008082 cites W2067224304 @default.
• W2096008082 cites W2073364837 @default.
• W2096008082 cites W2074795260 @default.
• W2096008082 cites W2079006650 @default.
• W2096008082 cites W2085464188 @default.
• W2096008082 cites W2088215603 @default.
• W2096008082 cites W2097001981 @default.
• W2096008082 cites W2100042048 @default.
• W2096008082 cites W2112359905 @default.
• W2096008082 cites W2117748999 @default.
• W2096008082 cites W2118532682 @default.
• W2096008082 cites W2119038745 @default.
• W2096008082 cites W2121525502 @default.
• W2096008082 cites W2126410775 @default.
• W2096008082 cites W2127595449 @default.
• W2096008082 cites W2127707303 @default.
• W2096008082 cites W2132083799 @default.
• W2096008082 cites W2135920807 @default.
• W2096008082 cites W2145077114 @default.
• W2096008082 cites W2151923895 @default.
• W2096008082 cites W2152263527 @default.
• W2096008082 cites W2152522850 @default.
• W2096008082 cites W2153292496 @default.
• W2096008082 cites W2162344297 @default.
• W2096008082 cites W4247037912 @default.
• W2096008082 doi "https://doi.org/10.1186/1710-1492-10-7" @default.
• W2096008082 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3936817" @default.
• W2096008082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24576338" @default.
• W2096008082 hasPublicationYear "2014" @default.
• W2096008082 type Work @default.
• W2096008082 sameAs 2096008082 @default.
• W2096008082 citedByCount "178" @default.
• W2096008082 countsByYear W20960080822014 @default.
• W2096008082 countsByYear W20960080822015 @default.
• W2096008082 countsByYear W20960080822016 @default.
• W2096008082 countsByYear W20960080822017 @default.
• W2096008082 countsByYear W20960080822018 @default.
• W2096008082 countsByYear W20960080822019 @default.
• W2096008082 countsByYear W20960080822020 @default.
• W2096008082 countsByYear W20960080822021 @default.
• W2096008082 countsByYear W20960080822022 @default.
• W2096008082 countsByYear W20960080822023 @default.
• W2096008082 crossrefType "journal-article" @default.
• W2096008082 hasAuthorship W2096008082A5005253283 @default.
• W2096008082 hasAuthorship W2096008082A5018170532 @default.
• W2096008082 hasAuthorship W2096008082A5022662950 @default.
• W2096008082 hasAuthorship W2096008082A5028760615 @default.
• W2096008082 hasAuthorship W2096008082A5033295100 @default.
• W2096008082 hasAuthorship W2096008082A5038468938 @default.
• W2096008082 hasAuthorship W2096008082A5050275340 @default.
• W2096008082 hasAuthorship W2096008082A5052394575 @default.
• W2096008082 hasAuthorship W2096008082A5054811067 @default.
• W2096008082 hasAuthorship W2096008082A5055694689 @default.
• W2096008082 hasAuthorship W2096008082A5058037343 @default.
• W2096008082 hasAuthorship W2096008082A5062378663 @default.

• next